Text
Why implementation is hard
Screening is not about expecting bad news. It is about reducing uncertainty, and giving you and your clinician more options while there are more options to have.
Dr. Scott Tackett
President & CEO
When we understand those systems, we can design solutions that work within them—and improve them.
Early cancer detection requires more than strong science and evidence. It requires solutions that fit real-world healthcare delivery and consistently reach everyone—not just the few.
Economics, social norms, governance, accessibility, availability, and affordability all shape whether evidence becomes better outcomes.
Improving cancer screening starts by understanding the system—and designing prevention around the people it’s meant to serve.
Originally shared on LinkedIn
Join the conversation and see how others have responded.
Advancing infrared applications for earlier detection — beginning with lung cancer.
AIR-DS is a UKCA marked in vitro diagnostic medical device, developed in accordance with IEC 62304 and under an ISO 13485 certified quality management system. In the US, a CLIA certified laboratory will offer a laboratory developed test (LDT) with AIR-DS Lung Test. It has not been cleared or approved by the FDA. Information on this website is provided for educational and informational purposes and should not be interpreted as medical advice.